Gynecologic Oncology
Clinical discussions on gynecologic malignancies, surgical approaches, and multimodal treatment strategies.
Recent Discussions
What are indications to add WPRT +/- PA field to chemotherapy for uterine serous carcinoma?
There is variation in practice. After adequate surgical staging, our approach: Stage 1A brachytherapy alone. Stage IB and above, EBRT. If node negative, treat pelvic including entire common iliac. If pelvis node positive and PA node dissected same as above, up to common iliac. If pelvis is posit...
How do you approach a medically inoperable patient with clinically stage 2 grade 1 endometrioid endometrial carcinoma with heavy vaginal bleeding that is refractory to EBRT and requiring inpatient management with transfusions?
Tough case that requires some individualized care- I’d favor brachy if not resectable.
What type of DVT/PE prophylaxis do you employ for an outpatient cervical brachytherapy?
We don’t use anything for outpatient HDR ICBT for cervical cancer.
Is there a difference in survival or disease response between patients with recurrence free interval ≥1 vs <1 year from platinum-based cytotoxic therapy who are treated with pembrolizumab + lenvatinib?
As presented by Dr. Columbo at ESMO 2021, the OS favored len/pem with an HR of 0.65 (0.52-0.81) in pMMR pts with a PFI <12 mo while the HR was 0.75 (0.36-1.58) in those with a PFI >12 mo.
How would you treat an isolated para-aortic lymph node endometrial cancer recurrence following a prolonged disease free interval previously treated with surgery, chemotherapy, and radiation therapy, if it is located outside of the previously irradiated field?
If no biopsy is done then surgery followed by adjuvant chemo and RT. If bx proven then based on nodal location and size, could be surgery and chemo RT or chemoRT without surgery.
Would you recommend adjuvant chemotherapy to a patient who has stage IB grade 1 endometrioid endometrial cancer with isolated tumor cells in two pelvic lymph nodes and extensive LVSI?
No. ITC is treated as n0. This patient should probably get whole pelvic RT +/- brachytherapy.
How would you treat a woman who has had a simple, extrafascial hysterectomy for a clinically occult, pathologically FIGO stage IB1 cervical cancer?
Standard would be to do some form of radical hysterectomy and if not done add adjuvant RT. That being said, the absolute risk of parametrial involvement for that size of disease is very low, and the benefit of RT if at all, is very small and requires a discussion of the pros and cons of intervention...
Given patients with substantial LVSI experience a pelvic recurrence rate of ~25%, how do you counsel patients with stage IA endometrioid endometrial cancer with LVSI regarding the relative risks/benefits of EBRT versus VBT alone?
Updated analysis of PORTEC-1 and 2 noted that 5-year pelvic lymph node recurrence was 26.3% when >4 vessels had LVSI involvement, compared to 6.7% with 1-3 foci and 3.3% with no LVSI1. Based on the data from PORTEC-2 which randomized patients to vaginal cuff brachytherapy or EBRT, on multivariable a...
Will you be changing your management of locally advanced cervical cancer based on the results of the recently published INTERLACE trial?
Absolutely NOT. INTERLACE results are in abstract form only, including early-stage disease I-II at 86%, and the details regarding radiation are minimal, stating it's prescribed to point A and recommend CT/MR planning (we do not know how many patients underwent image-guided brachytherapy). Also, ind...
For patients with advanced endometrial cancer, are the improved outcomes in PFS from DUO-E/RUBY/NRG-GY018 sufficient to move immunotherapy to the frontline for all presuming FDA approval?
The addition of immunotherapy to chemotherapy should certainly be considered the standard of care for patients with dMMR tumors. At the 2023 ESMO meeting, Dr. @Dr. First Last and team made a compelling argument to further strengthen the use of immunotherapy in the front line. Using the RUBY patient ...